MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma.
Bhutani M, Robinson M, Foureau D, Atrash S, Paul BA, Guo F, Grayson J, Ivanina-Foureau A, Pineda-Roman M, Varga C, Friend R, Ferreri CJ, Begic X, Norek S, Drennan T, Anderson MB, Symanowski JT, Voorhees PM, Usmani SZ.
Bhutani M, et al. Among authors: paul ba.
Blood Adv. 2024 Nov 22:bloodadvances.2024014417. doi: 10.1182/bloodadvances.2024014417. Online ahead of print.
Blood Adv. 2024.
PMID: 39576965